Advertise on podcast: The Regulatory Mix

On this episode of The Regulatory Mix, we break down FDA’s updated Concept of Operations for Facility Evaluation and Inspection of Human Drugs and answer a deceptively simple question: After the investigator leaves, who is actually reviewing my inspection? The answer depends on the type of inspection and what FDA is evaluating. The updated ConOps lays out how responsibilities are divided across Preapproval, Postapproval, Surveillance, and For-Cause inspections. OII generally leads the field inspection, while offices within CDER, including OPQ, OPMA, OQS, and OMQ, take on different roles in facility risk assessment, application decisions, inspection classification, and compliance follow-up. For a preapproval inspection, OPMA may be heavily involved because the question is whether the facility can support approval of a pending application. During routine surveillance, OQS helps drive risk-based site selection and develops the quality intelligence used before the inspection, while OMQ becomes particularly important when findings move toward VAI or OAI classification and potential compliance action. The document also shows how FDA is increasingly blending traditional inspections with Remote Regulatory Assessments, Section 704(a)(4) records requests, Remote Interactive Evaluations, and Mutual Recognition Agreement inspection reports. The inspection is only one piece of a much larger facility evaluation process. That means your Form FDA 483 response may ultimately be evaluated alongside application commitments, prior inspection history, complaints, recalls, quality intelligence, remote records, and information from other regulatory authorities. The takeaway: the investigator may conduct the inspection, but the regulatory decision can involve several different offices after the inspection is over. Understanding who owns that next decision helps explain why inspection responses need to address more than just the individual observations on the Form FDA 483. Source:FDA – Integration of FDA Facility Evaluation and Inspection Program for Human Drugs: A Concept of Operationshttps://www.fda.gov/media/107225/download?attachment Disclosure:The views expressed in this episode are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice.

On this episode of The Regulatory Mix, the discussion focuses on a major new policy shift affecting peptide compounding under Section 503A. HHS has announced an interim enforcement discretion policy allowing certain state-licensed pharmacies, federal facilities, and licensed physicians to compound drug products using six specified peptide bulk drug substances: BPC-157, Epitalon, KPV, MOTS-c, Semax, and TB-500, provided the policy’s conditions are met. The significance is not that these peptides are now FDA-approved or formally added to the 503A Bulks List. Rather, HHS is creating an interim pathway while formal rulemaking continues. That makes this a meaningful change for compounders, prescribers, and patients who have been operating in a much more restrictive environment around these substances. The policy also comes with significant conditions around sourcing, analytical testing, labeling, adverse event reporting, patient-specific prescriptions, route of administration, and product configuration. In other words, this is not a blanket green light. It is a tightly conditioned enforcement discretion framework. The bigger story is what this signals about the future of peptide compounding. HHS is clearly willing to create a controlled pathway for certain high-interest peptides while formal regulatory processes catch up, but the quality and documentation expectations remain substantial. The takeaway: this may open the door for peptide compounding, but it does not remove the need for strong sourcing controls, validated testing, patient-specific prescribing, and disciplined quality oversight. Sources:HHS Federal Register Public Inspection Notice:https://public-inspection.federalregister.gov/2026-22192.pdf HHS 503A Peptide Enforcement Discretion Policy — Appendix B:https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy-appendix-b.pdf Disclosure:Disclaimer: The views expressed in this episode are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.

On this episode of The Regulatory Mix, the discussion goes inside one of the most visual, and often misunderstood, elements of sterile manufacturing: the airflow visualization study, better known as the smoke study. At its core, a smoke study demonstrates that HEPA-filtered first air continues to protect exposed sterile product, components, and critical surfaces during actual operations. That means evaluating airflow not only at rest, but dynamically, with equipment running, operators in position, and representative interventions taking place. The episode explores what good airflow visualization should show: continuous unidirectional airflow over and away from critical areas, no problematic eddies or stagnant zones, and no operator or equipment movement that redirects lower-quality air toward exposed sterile surfaces. A system that looks perfect when empty can behave very differently once real operations begin. We also get into the practical side of execution. Fog generation method, manifold design, camera placement, lighting, tracer density, equipment positioning, and even how the fog is introduced can affect what the video appears to show. ASTM E3379-25 provides a modern framework for critical airflow visualization and reinforces that the goal is to demonstrate protection of the critical zone under representative conditions. EU GMP Annex 1 has further elevated airflow visualization by linking it to the broader Contamination Control Strategy (CCS). Smoke studies should not exist as isolated qualification videos. Their findings should influence intervention design, equipment placement, environmental monitoring locations, operator practices, and training. FDA’s aseptic processing guidance similarly treats airflow visualization as an important tool for demonstrating appropriate airflow patterns in critical areas. The expectation is not simply to create a dramatic cloud of smoke, but to produce meaningful evidence that the process environment protects sterile product. The takeaway is simple: a smoke study is not just a qualification video. It is a real-world test of facility design, equipment integration, operator behavior, intervention strategy, and contamination control. And once you spend time on the execution side, one thing becomes clear: getting the airflow right is only half the battle. Getting the camera angle, fog delivery, interventions, lighting, and documentation right enough to prove it can be an entirely different challenge. References & Links: ASTM E3379-25 – Standard Guide for Critical Airflow Visualization https://store.astm.org/e3379-25.html EU GMP Annex 1 – Manufacture of Sterile Medicinal Products https://health.ec.europa.eu/document/download/e05af55b-38e9-42bf-8495-194bbf0b9262_en FDA – Sterile Drug Products Produced by Aseptic Processing https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sterile-drug-products-produced-aseptic-processing-current-good-manufacturing-practice WHO Technical Report Series 961 https://www.who.int/publications/i/item/9789241209618 ISO 14644-3:2019 – Cleanrooms and Associated Controlled Environments — Test Methods https://www.iso.org/standard/60598.html USP – Pharmaceutical Compounding—Sterile Preparations https://doi.usp.org/USPNF/USPNF_M99925_09_01.html Disclosure: Disclaimer: The views expressed in this episode are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.

On this episode of The Regulatory Mix, the discussion focuses on FDA’s updated 2026 guidance for biosimilar and interchangeable biological products and what it means for development strategy, product design, pediatric requirements, and postapproval manufacturing. FDA’s latest Q&A reinforces an important principle: a biosimilar does not have to be an exact physical copy of its reference product. Sponsors may use different formulations, container closure systems, or delivery devices, and they may seek approval for fewer indications, presentations, or routes than the reference product. But that flexibility has clear statutory limits. A 351(k) applicant cannot use the abbreviated pathway to introduce a different strength, dosage form, route of administration, or an indication that has never been approved for the reference product. That creates some interesting strategic opportunities. A biosimilar may, for example, move from a vial presentation to a prefilled syringe or auto-injector if the sponsor can support the change with appropriate performance, stability, extractables and leachables, and human factors data. At the same time, converting a lyophilized “for injection” product into a ready-to-use “injection” crosses the statutory line because FDA considers those different dosage forms.  The episode also explores a less obvious area: pediatric requirements. Non-interchangeable biosimilars can trigger PREA obligations because they are treated as having a new active ingredient for PREA purposes, but FDA does not interpret that to mean biosimilar sponsors must develop pediatric indications, strengths, or dosage forms that the reference product itself does not have. The 351(k) pathway effectively limits the scope of those pediatric obligations. Postapproval manufacturing is another major theme. Once a biosimilar is licensed, manufacturers do not need to continue purchasing the reference product indefinitely every time they make a manufacturing change. FDA’s postapproval guidance allows routine comparability assessments to rely primarily on side-by-side evaluation of pre-change and post-change material, supported by a well-qualified in-house reference standard and ICH Q5E principles. That is a meaningful lifecycle advantage. Changes such as scale-up, facility transfers, purification modifications, or new presentations can be managed through the appropriate PAS, CBE, or Annual Report pathway based on risk. In some cases, sponsors can also leverage the comparative analytical assessment generated during the original 351(k) application rather than repeating a complete head-to-head exercise against new reference product lots. The broader takeaway is that FDA’s biosimilar framework has matured significantly. The pathway is not built around simply copying the innovator product forever. It is increasingly a lifecycle framework that gives sponsors meaningful flexibility while preserving strict boundaries around biosimilarity, product design, manufacturing comparability, and patient safety. FDA Sources:Questions and Answers on Biosimilar Development and the BPCI Act, Revision 4:https://www.fda.gov/media/119258/download Postapproval Manufacturing Changes to Biosimilar and Interchangeable Biosimilar Products: Q&As:https://www.fda.gov/media/180206/download Disclosure:Disclaimer: The views expressed in this episode are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.

On this episode of The Regulatory Mix, the discussion focuses on PIC/S Recommendation PI 006-4, which entered into force on October 1, 2026, and what it means for qualification and validation across pharmaceutical manufacturing. The revised recommendation supersedes PI 006-3 and reinforces a lifecycle, risk-based approach aligned with modern GMP expectations. The central message is clear: validation is no longer a one-time event. PI 006-4 reinforces a lifecycle model built around Quality Risk Management, data governance, ongoing verification, and disciplined change control. The goal is not simply to demonstrate that a process or system worked during an initial qualification exercise, but to prove that it remains in a state of control throughout its operational life. The episode explores the full qualification lifecycle, from User Requirements Specification and Design Qualification through FAT, SAT, IQ, OQ, PQ, and periodic review. It also highlights the increasing acceptance of science- and engineering-based approaches such as ASTM E2500, provided the manufacturer can demonstrate that systems are fit for intended use. Process validation receives particular attention. The old shorthand of “three consecutive batches” is no longer enough by itself. PIC/S emphasizes that the number of validation batches should be scientifically justified based on process understanding, risk, variability, and prior knowledge. Traditional validation, Continuous Process Verification, and hybrid approaches may all be appropriate depending on the maturity of the process and the available control strategy. The guidance is equally clear on what is no longer acceptable. Retrospective validation is explicitly rejected. Legacy processes must instead be supported through gap assessment, ongoing process verification, requalification where necessary, and evidence that the process remains capable and controlled. Cleaning validation also moves firmly into a toxicology- and risk-based model. Health-Based Exposure Limits should drive Maximum Allowable Carry-Over limits, and low-HBEL products may require automated cleaning, dedicated equipment, or routine analytical verification rather than reliance on highly variable manual cleaning alone. The broader principle is that cleaning must be demonstrated to be reproducible, not simply “tested until clean.” The episode also examines several operational areas that often receive less attention but carry real compliance risk: transport verification, utility qualification, packaging validation, test method suitability, and the control of direct and indirect product-contact systems. These expectations reinforce that validation extends far beyond manufacturing equipment alone. The takeaway is that PI 006-4 pushes industry toward a more mature definition of validation: not a protocol, not a binder, and not a fixed number of batches, but a continuous operating discipline. The firms that adapt best will be those that integrate QRM, process knowledge, statistical monitoring, change management, and lifecycle verification into the way manufacturing actually operates. PIC/S Source:Revision of PIC/S Recommendations on Qualification and Validation (PI 006-4)PIC/S PI 006-4 publication notice Disclosure:Disclaimer: The views expressed in this episode are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.

On this episode of The Regulatory Mix, the discussion focuses on what 30 FDA Human Drug and Biologic GMP Warning Letters issued through September 9, 2026 reveal about the Agency’s evolving enforcement strategy. The data show that FDA enforcement is becoming faster, broader, and less dependent on traditional on-site inspections. The median time from inspection close or records request to Warning Letter issuance was 176 days, but for many international facilities the Warning Letter was not the first consequence. Import Alert 66-40 frequently came first, meaning commercial impact often began weeks before the formal letter was issued. One of the clearest shifts is FDA’s expanded use of Section 704(a)(4) records requests. Several prescription and API manufacturers received Warning Letters based largely on remote document reviews, with FDA identifying serious deficiencies including missing process validation, absent stability programs, unvalidated analytical methods, and even data integrity manipulation without an investigator ever entering the facility. The underlying GMP failures, however, remain strikingly familiar. Inadequate investigations and Quality Unit oversight were each present in half of the letters analyzed. Sterility assurance, equipment and facility condition, cleaning validation, laboratory controls, stability, and data integrity continued to drive enforcement. Data integrity concerns have also evolved beyond simple backdating into more sophisticated forms of electronic manipulation involving trial injections, edited spectra, overwritten LIMS data, and software changes without audit trails. The analysis also shows that prior regulatory history is no guarantee of protection. Nearly one-quarter of the sites had never been inspected by FDA before the triggering action, yet several moved directly into OAI status, Import Alert, and Warning Letter territory. At the other end of the spectrum, some chronically poor-performing facilities continued to demonstrate repeat failures over multiple inspection cycles. International manufacturers face an especially challenging environment. Within this cohort, facilities in India and China received Warning Letters at substantially higher rates relative to closed FDA GMP inspections than U.S. facilities. The analysis also identified cases where active EU GMP documentation or positive European inspection outcomes did not prevent FDA from reaching an OAI conclusion and issuing a Warning Letter. The takeaway is that FDA’s enforcement model is becoming more continuous and intelligence-driven. Firms can no longer assume that the real regulatory risk begins when an investigator arrives on site—or even when a Warning Letter is posted. Import alerts, remote records reviews, supplier-chain tracing, and historical quality signals can all trigger consequences earlier. For industry, the message is straightforward: weak investigations, poor Quality Unit oversight, unresolved data integrity vulnerabilities, and fragile sterile manufacturing controls remain among the fastest ways to turn routine regulatory scrutiny into significant commercial risk. https://www.redica.com/resources/report/report---fda-warning-letters-to-human-drug-biologic-gmp-manufacturers Disclosure:Disclaimer: The views expressed in this episode are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.

On this episode of The Regulatory Mix, the discussion turns to FDA’s intensifying scrutiny of compounded GLP-1 medications and what the September 2026 Empower Pharmacy Warning Letter may signal for the broader compounding industry. During the semaglutide and tirzepatide shortages, compounding filled an important supply gap. But with those shortages resolved, FDA is applying much greater scrutiny to whether compounded products meet the statutory conditions of section 503A. At the center of the issue is a deceptively simple question: when does a customized formulation represent a legitimate patient-specific need, and when is it merely an “essentially identical” copy of an FDA-approved drug? The Empower case highlights that adding ingredients such as cyanocobalamin or niacinamide does not automatically establish a clinically significant difference. FDA focused on whether prescribers actually documented an individualized need for the modified formulation and whether repeated, standardized rationales across large numbers of prescriptions reflected genuine clinical judgment or something closer to mass production. That brings telehealth and automated prescribing workflows directly into the compliance discussion. Pre-populated checkboxes, required fields, and standardized “significant difference” language may improve workflow efficiency, but they can also undermine the individualized prescribing foundation on which section 503A relies. High production volumes combined with repeated identical justifications may become powerful compliance signals for FDA investigators. The episode also examines what happens when a compounder falls outside the conditions of section 503A. The consequences can move quickly beyond documentation deficiencies. Products may lose statutory exemptions and become subject to requirements involving approved applications, labeling, and CGMP. In the Empower case, FDA’s concerns also extended into aseptic processing, media fills, smoke studies, environmental monitoring, Quality Unit oversight, and data integrity. And the patient-safety issue goes beyond the manufacturing suite. Compounded GLP-1 products supplied in multidose vials can introduce dosing complexity that does not exist with many commercial pen products. Confusion between milligrams, milliliters, concentrations, and syringe “units” has contributed to significant dosing errors, reinforcing why labeling, formulation, dispensing, and patient instructions are all part of the risk equation. The takeaway is that the shortage-era environment is ending. For compounders, telehealth providers, and prescribers, GLP-1 compliance is increasingly about demonstrating that customization is genuinely patient-specific, clinically meaningful, and supported by defensible records. Adding a vitamin, checking a box, or repeating a standardized rationale is unlikely to substitute for individualized clinical judgment. FDA Warning Letter: Empower Clinic Services, LLC dba Empower Pharmacy, Warning Letter No. 738238, issued September 18, 2026:https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/empower-clinic-services-llc-dba-empower-pharmacy-738238-09182026 Disclosure:Disclaimer: The views expressed in this episode are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.

On this episode of The Regulatory Mix, the discussion takes a closer look at first-cycle Complete Response rates for CDER New Drug Applications and Biologics License Applications from FY 2008 through FY 2024. Recent industry commentary has suggested that Complete Response rates are structurally increasing. FDA’s own longitudinal analysis paints a more nuanced picture. The first-cycle CR rate for original NDAs and BLAs declined from approximately 47% in FY 2008 to about 27% in FY 2024. After a significant downward shift around FY 2011, rates largely stabilized around the 30% range rather than continuing on a sustained upward trajectory. (U.S. Food and Drug Administration⁠) The episode also explores why methodology matters when discussing approval statistics. Product-level approval data and submission-level PDUFA data are not interchangeable, and receipt cohorts can take multiple fiscal years to mature. Depending on the denominator, time period, and unit of analysis selected, very different narratives can emerge from what appears to be the same regulatory dataset. One of the most important findings is that a first-cycle Complete Response is not the same as ultimate failure. Across the period analyzed, the median first-cycle approval rate was approximately 64%, while roughly 77% of those original NDA and BLA applications are now in approved status after subsequent review cycles. (U.S. Food and Drug Administration⁠) The takeaway is that year-to-year fluctuations can generate headlines, but long-term data provide a better view of regulatory performance. The FDA analysis suggests that Complete Response rates are not on a persistent upward path and that many applications receiving an initial CR ultimately reach approval after deficiencies are addressed. For industry, the more useful question may not be whether CR rates are rising, but what separates applications that achieve first-cycle approval from those that require another round of review. Disclosure:Disclaimer: The views expressed in this episode are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client. Source:FDA Report: First-Cycle Complete Response Rates for CDER NDA and BLA Applications: A Longitudinal Analysis, FY 2008–2024https://www.fda.gov/media/194858/download

On this episode of The Regulatory Mix, we examine the growing intersection of artificial intelligence, pharmaceutical manufacturing, and regulatory accountability. As AI moves deeper into Current Good Manufacturing Practice environments, the key question is not whether firms will use it, but whether they can do so without weakening quality oversight, critical thinking, and compliance discipline. A recent FDA Warning Letter to Purolea Cosmetics Lab provides a clear example of what can go wrong when AI is used without meaningful human review. The firm relied on AI to generate product specifications, procedures, and production records, while basic CGMP responsibilities were not adequately understood or controlled. FDA specifically criticized the lack of Quality Unit oversight and the firm’s failure to recognize process validation requirements. The episode also looks at FDA’s emerging risk-based framework for evaluating AI credibility. The level of assurance required depends on three key factors: the model’s context of use, how much influence it has on a decision, and the consequence if that decision is wrong. The greater the model’s role and the higher the patient or product risk, the stronger the expectation for validation and oversight. Beyond compliance, the discussion turns to the effect of generative AI on human judgment. Research involving knowledge workers suggests that AI can shift cognitive effort away from direct problem-solving and toward verification and supervision. That can improve efficiency, but it also creates risks such as automation bias, reduced independent thinking, and skill atrophy when users become overly dependent on machine-generated outputs. The takeaway is simple: AI can assist regulated work, but it cannot assume regulatory responsibility. Accountability remains with the firm, the Quality Unit, and the qualified individuals responsible for ensuring that every decision affecting product quality and patient safety is scientifically sound and compliant. Reference Links:Purolea Cosmetics Lab Warning Letter:https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/purolea-cosmetics-lab-722591-04022026 FDA Draft Guidance on AI Model Credibility:https://www.fda.gov/media/184830/download Research: AI and Critical Thinkinghttps://www.microsoft.com/en-us/research/wp-content/uploads/2025/01/lee_2025_ai_critical_thinking_survey.pdf Disclaimer:The views expressed in this episode are personal opinions for educational purposes only and do not constitute legal, regulatory, or medical advice.

On this episode of The Regulatory Mix, the discussion revisits one of the most consequential strategic choices in drug development: whether a product belongs in a 505(j) ANDA or a 505(b)(2) application. FDA’s revised 2026 draft guidance, Determining Whether to Submit an ANDA or a 505(b)(2) Application, reads almost like a sequel to the Agency’s earlier framework—same core question, but with a more direct regulatory message: choose the pathway carefully, engage early, and do not assume flexibility where FDA believes an ANDA route is still scientifically available. The episode explores several important updates, including FDA’s more assertive direction to prospective applicants to engage the Office of Generic Drugs before committing to a development strategy. That matters most where a Reference Listed Drug has been discontinued, because the absence of a traditional reference standard does not automatically open the door to 505(b)(2). If FDA identifies an acceptable alternative method to establish bioequivalence, the Agency may still view 505(j) as the appropriate pathway and refuse to file a 505(b)(2) application. The discussion also covers the evolving therapeutic equivalence landscape. The 2026 draft reflects newer mechanisms that may allow certain 505(b)(2) applicants to request a therapeutic equivalence determination without relying solely on the traditional citizen petition process. That could have meaningful implications for pharmacy substitution, commercial uptake, and lifecycle strategy, particularly where the only difference from the reference product involves excipients that would not fit within standard ANDA requirements. Another important theme is that pathway selection is not simply a legal classification exercise. It affects development cost, clinical requirements, labeling strategy, patent and exclusivity considerations, substitution potential, and time to market. A decision that looks efficient early in development can become expensive very quickly if FDA determines that the application was built on the wrong statutory foundation. The broader takeaway is that FDA appears to be encouraging a conversation before the commitment. The revised guidance makes clear that sponsors should not treat ANDA versus 505(b)(2) as a late-stage filing decision. It is an early development strategy question that should be resolved before significant resources are committed to formulation work, bioequivalence studies, clinical programs, or commercial planning. Or, in Hamlet’s terms: 2(b), or not 2(b), really is the question—but FDA would prefer you ask before you spend the money. Reference link: https://www.fda.gov/media/160054/download Disclosure:Disclaimer: The views expressed are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.

On this episode of The Regulatory Mix, the discussion focuses on a growing strategic problem across the pharmaceutical industry: companies are making 20- and 30-year infrastructure investments in a world where demand forecasts, technologies, regulations, and geopolitical assumptions can change in only a few years. The episode examines major investments in peptide, API, and antibiotic manufacturing as companies race to secure capacity and reduce supply-chain dependence. Projects from Bachem, Aurobindo, and other manufacturers demonstrate the scale of the bet being made on future demand. But the strategic question is no longer simply whether additional capacity is needed. It is whether today’s highly specialized assets will still be commercially and technologically relevant by the time they are fully validated and operating at scale. That tension is becoming more important as regulators increase their focus on supply-chain resilience. In Europe, shortage prevention planning is placing greater responsibility on marketing authorization holders to understand vulnerabilities before a disruption occurs. In the United States, FDA organizational changes and continued updates to product-specific guidance reflect an environment in which regulatory expectations can evolve far faster than physical manufacturing infrastructure. The discussion also highlights why supply resilience cannot be separated from manufacturing quality. Recent FDA findings at sterile manufacturing facilities demonstrate the danger of allowing business urgency to override process understanding. Passing sterility tests, environmental monitoring, or final product testing does not compensate for recurring contamination events or weak investigations. Sterility assurance remains fundamentally process-based, and repetitive deviations that are explained away rather than understood can become evidence of a much larger quality-system failure. The same principle applies at the boardroom level. Organizations can create strategic risk when assumptions become progressively more optimistic simply to justify a major capital project or acquisition. Leadership teams should continually challenge which assumptions would leave the organization trapped if demand changes, a new modality emerges, regulations shift, or a competitor develops a fundamentally easier manufacturing route. The takeaway is that pharmaceutical resilience is no longer just about building more capacity. It is about building adaptable capacity supported by strong quality systems, diversified supply chains, regulatory awareness, and the ability to change direction before yesterday’s strategic advantage becomes tomorrow’s stranded asset. Disclosure:Disclaimer: The views expressed are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.

On this episode of The Regulatory Mix, the discussion turns to FDA’s draft Guidance for Industry #256B and a potentially significant expansion of the animal drug compounding landscape. The draft guidance addresses animal drugs compounded from bulk drug substances at federally registered facilities, including establishments registered under sections 503B(b) and 510(b) of the FD&C Act. The most important message is that FDA may exercise enforcement discretion for certain statutory requirements surrounding animal drug compounding, but it does not generally intend to extend that discretion to current good manufacturing practice violations. For federally registered facilities, compounded animal drugs from bulk substances would still be expected to be manufactured under CGMP. That distinction could be particularly important for 503B outsourcing facilities considering entry into the veterinary market. FDA’s concern is that allowing one portion of a registered facility to operate under CGMP while another produces drugs under a lower quality standard could create problems for inspections, regulatory clarity, and customer expectations regarding product quality. The draft also addresses facilities that may operate under both federal registration and state pharmacy authorities. If a facility intends to compound some animal drugs under the traditional pharmacy framework while producing others under the federally registered pathway, FDA expects clear segregation between those operations. Products not manufactured under CGMP would also need to be clearly distinguished so they are not confused with drugs produced under the facility’s federally registered operations. The broader implication is that this could create a new opportunity for outsourcing facilities already equipped with mature quality systems, validated processes, environmental controls, and CGMP infrastructure. But it is not simply a matter of adding veterinary products to an existing portfolio. Firms will need to understand the regulatory pathway, state-law implications, operational segregation requirements, labeling considerations, and the quality-system expectations that come with manufacturing inside a federally registered establishment. The takeaway is that FDA appears willing to create a pathway for broader animal drug compounding from bulk substances—but not at the expense of CGMP. For 503B facilities looking for new markets, the veterinary space may offer an opportunity, but the quality bar is not being lowered just because the patient has four legs. Disclosure:Disclaimer: The views expressed are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client. Source:FDA Draft Guidance for Industry #256B, Compounding Animal Drugs from Bulk Drug Substances in Federally-Registered Facilitieshttps://www.fda.gov/media/194414/download

On this episode of The Regulatory Mix, the discussion focuses on one of the most difficult questions facing regulated life sciences: how do you validate a system that may not give you the exact same answer twice? As generative AI and machine learning move deeper into pharmaceutical, medical device, and GxP environments, regulators are beginning to take different approaches to managing that uncertainty. The emerging U.S. approach places greater emphasis on demonstrated performance, predefined acceptance criteria, benchmarking, real-world monitoring, and continued assessment for model drift. The European approach reflected in developing Annex 22 expectations is more conservative for critical GMP applications, emphasizing static or locked models, reproducibility, and strong limitations on the use of generative AI where outputs could directly affect product quality or patient safety. The episode explores why this distinction matters. Traditional computerized system validation was built largely around deterministic software: defined inputs, expected outputs, and repeatable test results. Large language models challenge that paradigm because variability is inherent to the technology. The regulatory question therefore becomes whether reproducibility must be designed into the architecture itself or whether variability can instead be characterized, bounded, monitored, and controlled statistically. The discussion also examines the proposed modernization of EU GMP Annex 11 and what it means beyond AI. Lifecycle validation, Quality Risk Management, requirements traceability, data integrity, access controls, supplier oversight, change management, and continued validated-state maintenance remain foundational expectations regardless of the technology being deployed. Using a cloud provider, commercial AI platform, or third-party foundation model does not transfer regulatory accountability away from the regulated company. Human oversight is another central issue. A person approving an AI output is not necessarily an effective control if that individual lacks the domain knowledge or AI literacy needed to recognize when the system is wrong. Meaningful human-in-the-loop oversight therefore requires both technical understanding and subject-matter expertise, as well as awareness of automation bias and the natural tendency to trust confident machine-generated answers. The takeaway is that AI does not eliminate traditional validation principles—it puts pressure on them. The industry now has to determine how concepts such as intended use, risk, traceability, change control, supplier qualification, data integrity, and continued verification apply to systems whose behavior may be probabilistic rather than fixed. The firms that solve this problem will not simply be the ones adopting AI fastest, but those that can demonstrate that its variability is understood, controlled, and appropriate for its intended GxP use. Disclaimer: The views expressed are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.

On this episode of The Regulatory Mix, the discussion focuses on FDA’s newly issued draft guidance, Container Closure Systems for Human Drugs and Biological Products, which represents a major modernization of the Agency’s expectations for pharmaceutical packaging. The guidance moves container closure systems beyond a traditional packaging-function mindset and places them squarely within a lifecycle, risk-based pharmaceutical quality framework. A central theme is that container closure systems must be evaluated as an integral part of the drug product. Sponsors are expected to understand how materials, components, manufacturing processes, sterilization, storage, transportation, and product formulation interact over time. Suitability is product-specific, meaning a container closure system that works well for one dosage form or formulation may not be appropriate for another. The guidance places particular emphasis on extractables and leachables, with risk-based expectations that vary according to dosage form, route of administration, duration of exposure, and toxicological concern. For many chronic-use products, FDA discusses a 1.5 μg/day Safety Concern Threshold, while recognizing that substantially lower limits may be appropriate for higher-risk compounds such as nitrosamines and other DNA-reactive impurities. This reinforces the need to connect material characterization, toxicological assessment, and long-term stability into one coherent control strategy. Another major focus is Container Closure Integrity Testing (CCIT). FDA increasingly favors deterministic methods that provide scientifically meaningful measurements of system integrity over traditional probabilistic approaches such as dye ingress or microbial challenge testing. The guidance also calls attention to an increasingly important challenge for biologics and advanced therapies: ultra-low-temperature storage. Elastomeric components can temporarily lose sealing capability under extreme cold conditions and then reseal after warming, potentially masking failures if testing is performed only at room temperature. The draft also signals stronger expectations around materials of construction, secondary packaging, and supplier controls. Potential migration is no longer limited to materials in direct product contact; inks, adhesives, desiccants, and other secondary packaging components may also require assessment when volatile compounds can migrate through semi-permeable primary packaging. The broader takeaway is that container closure systems should no longer be treated as a late-stage packaging decision. They are part of the drug product’s safety, stability, sterility assurance, delivery performance, and overall control strategy. The firms best positioned under this modernized framework will be those that integrate container closure science early in development and maintain that understanding through commercial manufacturing, stability, change management, and the post-approval lifecycle. Source: FDA Draft Guidance: Container Closure Systems for Human Drugs and Biological Products https://www.fda.gov/media/194220/download Disclaimer: The views expressed are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.

On this episode of The Regulatory Mix, the discussion turns to one of the most consequential manufacturing stories in pharmaceuticals: the global surge in peptide capacity driven by unprecedented demand for GLP-1 therapies. What began as a breakthrough drug-development story has rapidly become an industrial-scale challenge involving metric-ton peptide production, sterile fill-finish capacity, global patent strategy, and billions of dollars in new manufacturing investment. The episode explores how India, China, and South Korea are racing to build the infrastructure needed to support the next phase of the GLP-1 market. From large-scale solid-phase peptide synthesis to recombinant manufacturing and specialized CDMO capabilities, companies across APAC are making substantial capital bets that peptide demand will remain durable well beyond the current branded-product cycle. But capacity alone may not determine the winners. Cost, quality, regulatory reliability, technology-transfer speed, and the ability to pivot across different peptide platforms may prove far more important than simply adding reactors. The discussion also examines the emerging regulatory fault line over whether certain complex peptides should be classified as drugs or biological products. That distinction carries significant consequences. Drug-versus-biologic classification can affect regulatory pathways, statutory exclusivity, pharmacy compounding, biosimilar competition, and the timing of government price negotiation. Cases involving lanreotide and newer GLP-1 molecules highlight how something as technical as the number and type of amino acids in a molecule can have enormous commercial and legal implications. At the same time, the manufacturing boom carries substantial durability risk. Sterile fill-finish and device assembly may remain more limiting than peptide API itself, while next-generation dual and triple agonists could require different production strategies. Perhaps the biggest long-term threat is the rise of non-peptide oral therapies. If small-molecule oral GLP-1 drugs can deliver comparable clinical performance with simpler manufacturing and distribution, some of today’s highly specialized peptide infrastructure could face pressure before those investments are fully amortized. The takeaway is that the GLP-1 opportunity is no longer just about scientific innovation or patent expiry. It is becoming a strategic contest over manufacturing capability, regulatory classification, supply-chain control, and technological adaptability. The companies most likely to succeed will be those that invest not merely in capacity, but in flexible platforms capable of supporting whatever the next generation of metabolic therapies looks like. Disclosure: Disclaimer: The views expressed are personal opinions for educational and discussion purposes only and should not be interpreted as legal, regulatory, medical, or investment advice. These views do not represent those of any current or former employer, agency, or client.